2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-1H,4H-imidazo[4,3-f][1,2,4]triazin-4-one

• ChemBase编号: 740
• 分子式: C23H32N6O4S
• 平均质量: 488.60298
• 单一同位素质量: 488.22057453
• SMILES: S(=O)(=O)(N1CCN(CC1)CC)c1cc(c(OCC)cc1)c1[nH]n2c(nc(c2c(=O)n1)C)CCC
• Canonical SMILES: CCOc1ccc(cc1c1nc(=O)c2n([nH]1)c(CCC)nc2C)S(=O)(=O)N1CCN(CC1)CC
• InChI: InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)
• InChIKey: SECKRCOLJRRGGV-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-1H,4H-imidazo[4,3-f][1,2,4]triazin-4-one
• IUPAC传统名: vardenafil
• 商标名: Levitra
• 别名: VDN; Vardenafil

登记号

• CAS号: 224785-90-4
• PubChem SID: 46506777; 160964203
• PubChem CID: 110634

理论计算性质

JChem

• Acid pKa: 8.007337
• 质子受体: 8
• 质子供体: 1
• LogD (pH = 5.5): 0.6368539
• LogD (pH = 7.4): 1.3132267
• Log P: 1.3251204
• 摩尔折射率: 142.7097 cm^3
• 极化性: 50.337387 Å^3
• 极化表面积: 109.13 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.18
• LOG S: -3.18
• 溶解度: 3.25e-01 g/l

分子性质

理化性质

• 溶解度: 0.11 mg/mL (HCl salt)
• 疏水性(logP): 1.4

详细说明

DrugBank - DB00862

• Drug Groups: approved
• Description: Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
• Indication: Used for the treatment of erectile dysfunction
• Pharmacology: Vardenafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzyme guanylate cyclase which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation in the corpus cavernosum, resulting in increased inflow of blood and an erection. Vardenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. This means that, with vardenafil on board, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, vardenafil should not cause an erection.
• Toxicity: Symptoms of overdose include vision changes and back and muscle pain.
• Affected Organisms: Humans and other mammals
• Biotransformation: Vardenafil is metabolized predominantly by the hepatic enzyme CYP3A4, with contribution from the CYP3A5 and CYP2C isoforms. The major circulating metabolite, M1, results from desethylation at the piperazine moiety of vardenafil. M1 shows a phosphodiesterase selectivity profile similar to that of vardenafil and an in vitro inhibitory potency for PDE5 28% of that of vardenafil.
• Absorption: Vardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.
• Half Life: 4-5 hours
• Protein Binding: 95%
• Elimination: After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered oral dose) and to a lesser extent in the urine (approximately 2-6% of administered oral dose).
• Distribution: * 208 L
• Clearance: * 56 L/h
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com